

Imperial College London - Freedom of Information Request - IMPFOI-25-193

Over the last two reporting years, what was the total aggregate sum of health research funding received by The University from each of the following 20 pharmaceutical companies? Please specify the currency in which the funding was received (e.g., EUR, GBP, USD).

Novartis AG; GSK plc; Sanofi; Pfizer Inc; AstraZeneca plc; Johnson & Johnson; Merck KGaA; Boehringer Ingelheim; Takeda Pharmaceutical Co, Ltd; Bayer AG; Roche Holding AG; Novo Nordisk A/S; Bristol Myers Squibb; Eisai Co, Ltd; Astellas Pharma Inc; Gilead Sciences; Merck & Co, Inc; Daiichi Sankyo Co, Ltd; Eli Lilly & Co; AbbVie Inc.

IMPFOI-25-193		GL Financial Year		
Award Original Funder	Award Invoice Currency *	2022/2023	2023/2024	Grand Total
AbbVie Inc	USD	£ 49,229.14		£ 49,229.14
Astra Zeneca Pharmaceuticals	GBP	£ 73,403.14	£ 120,493.68	£ 193,896.82
AstraZeneca AB	GBP	£ 867,531.91	£ 560,587.61	£ 1,428,119.52
AstraZeneca Pharmaceuticals LP	GBP		£ 14,915.75	£ 14,915.75
AstraZeneca UK Limited	GBP	£ 1,648,696.96	£ 1,561,888.33	£ 3,210,585.29
AstraZeneca UK Limited	USD	£ 510,987.50		£ 510,987.50
Bayer AG	GBP	£ 97,539.93	£ 302,021.14	£ 399,561.07
Bayer Uk Plc	GBP	£ 15,119.76		£ 15,119.76
Boehringer Ingelheim International GmbH	GBP	£ 888,330.75	£ 165,846.53	£ 1,054,177.28
Boehringer Ingelheim Ltd	GBP	£ 554,060.39	£ 277,427.88	£ 831,488.27
Boehringer Ingelheim Pharma GmbH & Co KG	GBP	£ 167,282.58	-£ 2,140.62	£ 165,141.96
Boehringer Ingelheim Pharma GmbH & Co. KG	GBP	£ 1,559.33		£ 1,559.33
Bristol Myers Squibb	GBP	£ 742,501.22	£ 320,196.30	£ 1,062,697.52
Bristol Myers Squibb Pharmaceuticals Ltd (0034)	GBP	£ 131,498.72	£ 418,152.72	£ 549,651.44
Eisai Europe Ltd	GBP	£ 1,236.94		£ 1,236.94
Eli Lilly & Company (USA)	GBP	£ 491,993.49	£ 41,522.48	£ 533,515.97
Eli Lilly & Company (USA)	USD	£ 122,717.36	£ 12,214.86	£ 134,932.22
Gilead Sciences Inc	EUR		£ 4,024.22	£ 4,024.22
Gilead Sciences Inc	GBP	£ 36,231.97	£ 21,329.42	£ 57,561.39
Gilead Sciences Inc	USD	£ 30,460.16	£ 141,048.85	£ 171,509.01
Gilead Sciences Ltd	GBP	£ 234,362.79	£ 232,502.06	£ 466,864.85
Glaxo Smithkline S.P.A	GBP		-£ 400.88	-£ 400.88
GlaxoSmithKline	GBP	£ 154,670.43	£ 338,833.98	£ 493,504.41
GlaxoSmithKline Biologicals	GBP	£ 356,968.30	£ 362,218.30	£ 719,186.60
Glaxosmithkline Research and Development Ltd	GBP	£ 581,020.95	£ 164,414.41	£ 745,435.36
GlaxoSmithKline Services Unlimited	GBP	£ 116,738.37	£ 301,848.55	£ 418,586.92
Novartis Pharma AG	GBP	£ 173,047.28	£ 125,913.26	£ 298,960.54
Novartis Pharma AG	USD	-£ 188.41		-£ 188.41
Novartis Pharmaceuticals UK Limited	GBP	£ 103,735.45	£ 213,811.79	£ 317,547.24
Novo Nordisk A/S	DKK	£ 42,900.23	£ 56,011.42	£ 98,911.65
Novo Nordisk A/S	GBP	£ 336,996.49	£ 518,253.50	£ 855,249.99
Pfizer Incorporated	EUR	£ 5,330.22		£ 5,330.22
Pfizer Incorporated	GBP	£ 82,858.34	£ 6,722.14	£ 89,580.48
Pfizer Incorporated	USD	£ 82,351.64	£ 21,917.33	£ 104,268.97
Pfizer Limited	GBP	£ 483,759.33	£ 63,460.13	£ 547,219.46
Sanofi Aventis	GBP	£ 835,957.52	£ 944,095.01	£ 1,780,052.53
Sanofi Genzyme Europe B.V.	GBP	£ 59,395.55	£ 5,903.85	£ 65,299.40
Grand Total		£ 10,080,285.73	£ 7,315,034.00	£ 17,395,319.73

* Invoice currency is the currency which Imperial must invoice the funder. Our expenditure values are all GBP which is due to the majority of our expenditures being GBP. One funder may have grants in multiple currencies so appears multiple lines.

Note: given that these appear to be pharmaceutical companies, we have made the assumption that all of the research funded is healthcare, we have not investigated them individually.